drugset / Trial / NCT00216294
Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder
Phase 2
Completed
12 enrolled
Indiana University
Repligen Corporation · collabShekhar, Anantha M.D., Ph.D. · collab
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on OCD patients' anxiety, quality of life, and depression.
Timeline
- Start
- 2005-02
- Primary completion
- 2006-04
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RG1068 | Peptide | 10 ug/kg | Subcutaneous |
| Subject | RG1068 | Peptide | 20 ug/kg | Subcutaneous |